Australia’s drug watchdog sounds alarm over mental health and contraception risks in popular weight-loss treatments — including Ozempic.
Australia’s Therapeutic Goods Administration (TGA) has introduced two new cautionary updates, raising concerns about possible mental health side effects and contraception complications linked to well-known diabetes and weight-loss drugs.
These medications, known as GLP-1 receptor agonists, have surged in popularity in recent years — but now come with a serious caveat. The regulator warns that users and healthcare professionals need to be alert for emerging signs of depression, suicidal thoughts, or disturbing shifts in mood. According to the TGA, reports of suicidal ideation and behavior have surfaced among some patients prescribed these newer treatments. Because of this, doctors are being urged to carefully monitor anyone starting or adjusting doses of drugs like Ozempic, Wegovy, Saxenda, Trulicity, and Mounjaro.
But here’s where it gets even more complicated — and potentially controversial. Alongside the mental health update, the TGA has singled out Mounjaro for a separate advisory involving birth control. After reviewing available data, regulators found signals suggesting that the drug might reduce the effectiveness of oral contraceptives when a person first starts taking it or when the dosage is increased. Although a direct link couldn’t be definitively proven, the TGA says it’s taking a precautionary stance.
To minimize any possible risk, product guidance for Mounjaro now recommends that individuals relying on oral contraception either switch to non-oral alternatives or use an additional barrier method — such as condoms — for at least four weeks after beginning treatment and for another four weeks following each dose increase.
The agency also emphasized one firm rule across all GLP-1 receptor agonist medications: none of these drugs should be used during pregnancy.
And this is the part most people miss — while GLP-1 drugs are often praised as game changers for weight management and diabetes care, questions remain about the full scope of their side effects. Are these mental health and reproductive warnings early signs of deeper systemic issues, or just a cautious approach to limited data?
What do you think — are these new warnings justified precaution, or a sign we’re still learning too little about how these breakthrough weight-loss drugs truly affect the body?
